- Home
- SATL vs AMRN Comparison
SATL vs AMRN Comparison
Compare SATL & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SATL
- AMRN
- Stock Information
- Founded
- SATL 2010
- AMRN 1989
- Country
- SATL United States
- AMRN Ireland
- Employees
- SATL N/A
- AMRN N/A
- Industry
- SATL Radio And Television Broadcasting And Communications Equipment
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- SATL Technology
- AMRN Health Care
- Exchange
- SATL Nasdaq
- AMRN Nasdaq
- Market Cap
- SATL 373.7M
- AMRN 302.0M
- IPO Year
- SATL N/A
- AMRN 1993
- Fundamental
- Price
- SATL $3.77
- AMRN $19.25
- Analyst Decision
- SATL
- AMRN Strong Sell
- Analyst Count
- SATL 0
- AMRN 1
- Target Price
- SATL N/A
- AMRN $12.00
- AVG Volume (30 Days)
- SATL 2.4M
- AMRN 90.2K
- Earning Date
- SATL 11-12-2025
- AMRN 10-29-2025
- Dividend Yield
- SATL N/A
- AMRN N/A
- EPS Growth
- SATL N/A
- AMRN N/A
- EPS
- SATL N/A
- AMRN N/A
- Revenue
- SATL $13,868,000.00
- AMRN $219,361,000.00
- Revenue This Year
- SATL N/A
- AMRN N/A
- Revenue Next Year
- SATL N/A
- AMRN N/A
- P/E Ratio
- SATL N/A
- AMRN N/A
- Revenue Growth
- SATL 1.09
- AMRN N/A
- 52 Week Low
- SATL $0.93
- AMRN $7.08
- 52 Week High
- SATL $5.49
- AMRN $20.43
- Technical
- Relative Strength Index (RSI)
- SATL 54.32
- AMRN 85.05
- Support Level
- SATL $3.45
- AMRN $15.24
- Resistance Level
- SATL $3.85
- AMRN $20.43
- Average True Range (ATR)
- SATL 0.22
- AMRN 0.75
- MACD
- SATL 0.02
- AMRN 0.44
- Stochastic Oscillator
- SATL 55.19
- AMRN 80.71
About SATL Satellogic Inc.
Satellogic Inc is a provider of satellite imagery to governments and commercial customers globally. It geographically operates in North America, Europe, Asia and South America. It derives maximum revenue from Asia Pacific.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.